

AUSTRALIA
Patents Act 1990

NOTICE OF ENTITLEMENT

I,

THE UNITED STATES OF AMERICA,
as represented by THE SECRETARY,
U.S. DEPARTMENT OF COMMERCE

of

5285 PORT ROYAL ROAD
SPRINGFIELD, VA 22161
U.S.A.

being the applicant in respect of this Application state
the following:-

The person(s) nominated for the grant of the patent:

The nominated person is the assignee of the said inventors.

The person(s) nominated for the grant of the patent:


The applicant and nominated person is the basic applicant.

The basic application(s) listed in the declaration made
under Article 8 of the PCT is/are the first application(s)
made in a Convention country in respect of the invention.

THE UNITED STATES OF AMERICA,
as represented by THE SECRETARY,
U.S. DEPARTMENT OF COMMERCE

03rd March 1992

GRIFFITH HACK & CO.



Patent Attorneys for and
on behalf of the applicant.




AU9065226

(12) PATENT ABRIDGMENT (11) Document No. AU-B-65226/90
 (19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 638499

- (54) Title
 ANTI-HYPERTENSIVE COMPOSITIONS OF SECONDARY AMINE-NITRIC OXIDE ADDUCTS AND USE THEREOF
- (51)⁵ International Patent Classification(s)
 A61K 031/13 A61K 031/40 A61K 031/445 A61K 031/495
 A61K 031/535
- (21) Application No. : 65226/90 (22) Application Date : 07.09.90
- (87) PCT Publication Number : WO91/04022
- (30) Priority Data
- (31) Number (32) Date (33) Country
 409552 15.09.89 US UNITED STATES OF AMERICA
- (43) Publication Date : 18.04.91
- (44) Publication Date of Accepted Application : 01.07.93
- (71) Applicant(s)
 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE
- (72) Inventor(s)
 LARRY KAY KEEFER; JOSEPH ANTHONY HRABIE; TAMBRA MARIE DUNAMS; DAVID ANDERSON WINK
- (74) Attorney or Agent
 GRIFFITH HACK & CO , GPO Box 1285K, MELBOURNE VIC 3001
- (57) Claim

1. A pharmaceutical composition comprising: a compound of the formula



wherein R_1 and R_2 are independently chosen from the group consisting of a straight chain or branched chain C_1 - C_{12} alkyl group and a benzyl group with the proviso that no branch occur on the alpha carbon atom. or R_1 and R_2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M^{+x} is a pharmaceutically acceptable cation, wherein x is the valence of the cation; and a pharmaceutically acceptable carrier.


8. A method of treating cardiovascular disorders in mammals

(11) AU-B-65226/90

-2-

(10) 638499

by lowering the blood pressure which comprises administering to a mammal, in need thereof, a blood pressure lowering effective amount of a compound of the formula:



wherein R_1 and R_2 are independently chosen from the group consisting of a straight chain or branched chain C_1 - C_{12} alkyl group and a benzyl group, with the proviso that no branch occur on the alpha carbon atom, or R_1 and R_2 , together with the nitrogen atom they are bonded to, form a pyrrolidino, piperidino, piperazino or morpholino group; and M^{+x} is a pharmaceutically acceptable cation, wherein x is the valence of the cation.

OPI DATE 18/04/91

APPLN. ID

65226 / 90

PCT

AOJP DATE 30/05/91

PCT NUMBER PCT/US90/05018

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/13, 31/40, 31/445 A61K 31/495, 31/535	A1	(11) International Publication Number: WO 91/04022 (43) International Publication Date: 4 April 1991 (04.04.91)
(21) International Application Number: PCT/US90/05018 (22) International Filing Date: 7 September 1990 (07.09.90) (30) Priority data: 409,552 15 September 1989 (15.09.89) US (71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, U.S. DEPARTMENT OF COMMERCE [US/US]; 5285 Port Royal Road, Springfield, VA 22161 (US). (72) Inventors: KEEFER, Larry, Kay ; 7016 River Road, Bethesda, MD 20817 (US). HRABIE, Joseph Anthony ; 1703 West 7th Street, Apt. 202, Frederick, MD 21701 (US). DUNAMS, Tamara, Marie ; Q-301 Waverly Drive, Frederick, MD 21701 (US). WINK, David, Anderson ; 8228 Red Wing Court, Frederick, MD 21701 (US).	(74) Agents: HOLMAN, John, Clarke et al.; Fleit, Jacobson, Cohn, Price, Holman & Stern, The Jenifer Building, 400 Seventh Street, N.W., Washington, DC 20004 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>	
(54) Title: ANTI-HYPERTENSIVE COMPOSITIONS OF SECONDARY AMINE-NITRIC OXIDE ADDUCTS AND USE THEREOF $(I) \quad \left(\begin{array}{c} R_1 \\ \diagdown \\ N - N - O^- \\ \diagup \\ R_2 \end{array} \begin{array}{c} \\ \\ \vdots \\ \\ N=O \end{array} \right)_x M^{+x}$ (57) Abstract This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of formula (I), wherein R₁ and R₂ are independently chosen from straight chain and branched chain C₁-C₁₂ alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R₁ and R₂ together with the nitrogen atom are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group M⁺x is a pharmaceutically acceptable cation, wherein x is the valence of the cation.		

638499

- 1 -

ANTI HYPERTENSIVE COMPOSITIONS OF SECONDARY AMINE-NITRIC OXIDE
ADDUCTIONS AND USE THEREOF


Introduction

This invention concerns novel pharmaceutical compositions and a method of treating hypertension. Related compositions and methods are described in US patent application SN 07/316,958, filed 2/28/89 and in SN 7,423,277, filed 10/18/89.

Background of the Invention

Endothelium-derived relaxing factor (EDRF) is a labile humoral agent which is part of a cascade of interacting agents involved in the relaxation of vascular smooth muscle. EDRF is thus important in the control of vascular resistance to blood flow and in the control of blood pressure. Some vasodilators act by causing EDRF to be released from endothelial cells. (See Furchgott, Ann.Rev.Pharmacol.Toxicol. 24, 175-197, 1984.) Recently, Palmer et al. have shown that EDRF is identical to the simple molecule, nitric oxide, NO. (Nature 317, 524-526, 1987.) It has been hypothesized for years that many nitrovasodilators that mimic the effect of EDRF, like glyceryl trinitrate, amyl nitrite, NaNO_2 and sodium nitroprusside (SNP), do so by virtue of their conversion to a common moiety, namely NO, which is also a vasodilator. (See Kruszona et al., Tox.& Appl. Pharmacol., 91, 429-438, 1987; Ignarro, FASEB J. 3, 31-36, 1989)


and Ignarro et al., J. Pharmacol. Exper. Therapeutics 218(3), 739-749, 1981.) It has now been discovered that a class of compounds of the structure:



wherein A is a secondary amino group, are potent anti-hypertensives and thus are useful for treating cardiovascular disorders in which lowering the blood pressure has a beneficial result. It is believed that these compounds function by releasing NO in the blood after injection; however the invention should not be limited by this hypothesis. While these compounds are, for the most part, known, there is no suggestion in the prior art that they are anti-hypertensive, indeed, there is no suggestion in the prior art that these compounds have any pharmaceutical use. They are described by Drago in "Free Radicals in Inorganic Chemistry", Number 36, Advances in Chemistry Series, American Chemical Society, Wash. DC, 1962, pages 143-149 and Drago et al. J. Amer. Chem. Soc. 83, 1819-1822, 1961. These two articles by Drago are incorporated by reference, in their entirety. The references are of a theoretical nature and mention no utility whatsoever. Reilly, US Patent 3,153,094, discloses these compounds on columns 11-13, but does not teach any biological activity.

Description of the Invention

The present invention provides pharmaceutical compositions comprising: a compound of the following formula



wherein R_1 and R_2 are independently chosen from straight chain and branched chain alkyl groups of one to twelve carbon atoms or benzyl, with the proviso that no branch occur on the alpha carbon of the alkyl groups, or R_1 and R_2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino ring, M^{+X} is a pharmaceutically acceptable cation, wherein x is the valence of the cation (its charge); and a pharmaceutically acceptable carrier. By straight chain alkyl is meant the non-branched methyl, ethyl, n-propyl, n-butyl, n-decyl, and etc. groups. By branched chain alkyl is meant groups like 3-methylpentyl, 2-ethylpropyl, and etc. The proviso means that groups like isopropyl or 1-methylbutyl are excluded. The C_2 to C_6 alkyls are preferred. Of the R_1R_2N - heterocyclic groups, morpholino is preferred. By a pharmaceutically acceptable cation is meant any non-toxic cation; these are well known to one of ordinary skill in the art. The cation should not render the compound unstable or insoluble in water. Generally the cation will be a group 1 or group 2 cation, such as sodium, potassium, magnesium or calcium ions, or $NR_3R_4R_5R_6^+$, wherein R_3 , R_4 , R_5 , and R_6 are independently chosen from H, C_1 - C_{12} alkyl, C_3 - C_7 cycloalkyl or benzyl, more preferably H, C_1 - C_4 alkyl or C_6 cycloalkyl. The method of synthesis discussed below first results in the cation

being $R_1R_2H_2N^+$, these cations work well. The most preferred cations are Na^+ , K^+ , Ca^{+2} , and $R_1R_2H_2N^+$.

The compositions are potent anti-hypertensives. They are useful for lowering the blood pressure and treating any cardiovascular disorder in which lowering the blood pressure will have a beneficial effect. The invention provides an effective method of lowering the blood pressure by administering the composition to a mammal.

The methods of synthesis are the same as disclosed by Drago et al., J. Amer. Chem. Soc., 83, 1819-1822, 1961. Generally, the secondary amine (R_1R_2HN) is dissolved in anhydrous ether, oxygen is removed from the system, the temperature is lowered to $-78^\circ C$, and dry NO is bubbled through the ether solution. The reaction can be run at high pressure (100 psi) or at atmospheric pressure. The same product is obtained, but the yields are higher using the high pressure method. The same method is used to make all the compounds, the only difference being the starting secondary amine. Example 1 gives the details of how the diethylamine complex was made.

Example 1a

Anhydrous diethylamine (100ml) was dissolved in 100ml of anhydrous diethyl ether and was placed in a three-necked flask. Two of the necks served as inlets for N_2 and NO, and the

third was an outlet. The flask was flushed with N_2 and the mixture cooled to $-78^\circ C$ using an acetone-dry ice bath. Commercial grade NO was bubbled through 10M NaOH and dried by passing it through a column containing NaOH pellets, and then bubbled for 3 hr through the diethylamine/diethyl ether solution. The mixture was allowed to warm to room temperature overnight (18 hr). The product precipitated from solution. The product was filtered and washed with diethyl ether. Three grams (3% yield) of crude product was obtained. The product was purified by suspending it in diethyl ether, adding sufficient neutralized chloroform dropwise to just dissolve the product, and placing the mixture in the freezer. The resultant crystals were then filtered, washed with diethyl ether and dried by vacuum.


1H NMR (200MHz): δ 3.07 (q, 4H, $J=7.2$ Hz), 2.94 (q, 4H, $J=7.2$ Hz), 1.27 (t, 6H, $J=7.2$ Hz), 0.96 (q, 6H, $J=7.2$ Hz).

^{13}C NMR (50MHz): δ 51.3, 45.2, 13.8, 13.5.

Calculated: C=46.56%, N=27.17%, H=10.75%

Found: C=46.49%, N=26.29, H=11.20%

The above physico-chemical characteristics correspond to the structure:



Example 1b

In the high pressure method a Parr shaker was used. NO was added to the reservoir which makes it possible to fill the

reaction vessel without opening it directly to the NO tank. The mixture of diethylamine (100ml) and diethyl ether (100 ml) was added to the reaction vessel. The reaction vessel was cooled to -78°C and subjected to several evacuation/nitrogen flush cycles to remove as much of the oxygen as possible. NO was then introduced at a pressure of about 100 psi. The reaction vessel was allowed to slowly warm to room temperature overnight (18 hr), with shaking. The excess NO was flushed off with N_2 and the product was filtered and washed with diethyl ether. The crude yield was 5 grams. Purification and analysis were the same as in example 1a.

The other secondary amine-NO complexes are made using the same methods as examples 1a and 1b, the only difference being the identity of the starting secondary amine. The product made in each case has the formula $\text{R}_1\text{R}_2\text{NN}_2\text{O}_2^-\text{R}_1\text{R}_2\text{H}_2\text{N}^+$. The synthesis of the salts containing the other cations is done by conventional methods, most particularly by a metathesis reaction, a method well known to one of ordinary skill in the art. (See Drago et al.) To make the sodium salt of the compound produced in example 1, the diethylammonium salt is dissolved in ethyl alcohol and reacted with sodium ethoxide according to the following reaction:

$$\text{R}_1\text{R}_2\text{NN}_2\text{O}_2^-\text{R}_1\text{R}_2\text{H}_2\text{N}^+ + \text{NaOEt} \rightarrow \text{EtOH} + \text{R}_1\text{R}_2\text{NH} + \text{R}_1\text{R}_2\text{NN}_2\text{O}_2^-\text{Na}^+$$

The product is precipitated by flooding the reaction mixture with ether and then washed with neutralized chloroform. The other salts can be made by similar metathesis reactions.

Pharmacological Properties

The effect on the mean arterial blood pressure and heart rate of male Sprague-Dawley rats of the compositions of the invention was measured using a standard technique. A pressure transducer (Bell and Howell, type 4-327-I) was connected to the right carotid artery via a catheter containing heparinized saline. The mean arterial pressure and heart rate were recorded on a Gould (Model 2800) 3-channel recorder. The rats were anesthetized with nembutal at an initial dose of 35 mg/kg body weight and recurrent smaller injections as needed. The compounds were dissolved in a pharmaceutical carrier and injected into the rats via a catheter in the right femoral vein. Table 1 shows the results.

TABLE 1

Compound	Dose (μ mole/kg)	Mean Arterial Pressure			Heart Rate	
		Initial	Post	Change	Initial	Post
		(mm Hg)			(beats/min)	
(Et) ₂ NN ₂ O ₂ (Et) ₂ H ₂	3.90	102	36	-66	480	480
SNP	0.34	113	56	-57	403	454
NaNO ₂	4.00	126	48	-78	360	420
NaNO ₃	42.00	117	120	3	420	420

In Table 1, the pharmaceutical carrier was Abbott's 5% dextrose USP. SNP, NaNO₂, and NaNO₃ were used as controls. SNP and NaNO₂ are known vasodilators, NaNO₃ is the oxidative breakdown product

of NaNO_2 and has little vasodilatory effect. The results show that $(\text{Et})_2\text{NN}_2\text{O}_2^-(\text{Et})_2\text{H}_2\text{N}^+$ is a potent anti-hypertensive, decreasing the blood pressure significantly. The peak value of the blood pressure decrease, shown in Table 1, takes only about 30 sec to 1 min to occur, after injection, and the blood pressure starts to rise again soon after and has totally recovered within 10-15 min.


The compositions of this invention are useful for treating any cardiovascular disorder that will respond favorably to a decrease in blood pressure. These disorders include chronic hypertension, hypertensive crisis (an acute hypertensive emergency), acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency and intracranial haemorrhage. Because of the fast response upon intravenous injection the compositions are particularly advantageous for treating acute disorders such as hypertensive crisis, toxemia of pregnancy and acute congestive heart failure. The preferred method of administration is by injection into the blood system, most preferably by intravenous injection. The chronic disorders can be treated by continuous intravenous infusion. A suitable dosage for intravenous administration is about 0.01 to 10.0 mg/kg per day.

The pharmaceutical compositions of the invention are comprised of the compounds of formula I and a pharmaceutical

carrier. The carrier can be any of those conventionally used and is limited only by chemico-physical considerations such as solubility and lack of reactivity with the compound and by the route of administration. For intravenous administration, the carrier will be aqueous and may contain solubilizing agents, buffers, preservatives, antioxidants, chelating agents, and agents to control the tonicity, such as dextrose or sodium chloride. The requirements for effective pharmaceutical carriers for injectable compositions are well known by one of ordinary skill in this art. (See "Pharmaceutics and Pharmacy Practice", J.B. Lippincott Company, Philadelphia, 1982, edited by Banker and Chalmers, pages 238-250, which are incorporated by reference, also see ASHP "Handbook on Injectable Drugs" 4th edition by Trissel, pages 622-630, which lists commercially available intravenous infusion solutions, these pages are incorporated by reference.) The compounds may also be formulated as inclusion complexes, such as, for example, cyclodextrin inclusion complexes; or the compounds may be carried within liposomes. Preferred pharmaceutical carriers for injection are PBS (phosphate buffered saline), 5% dextrose and sterile water. Since the compounds of formula I are subject to being oxidized by oxygen, an antioxidant, such as ascorbate, can be added to the carrier to increase the shelf-life.

What is claimed is:

1. A pharmaceutical composition comprising: a compound of the formula



wherein R_1 and R_2 are independently chosen from the group consisting of a straight chain or branched chain C_1 - C_{12} alkyl group and a benzyl group with the proviso that no branch occur on the alpha carbon atom. or R_1 and R_2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M^{+x} is a pharmaceutically acceptable cation, wherein x is the valence of the cation; and a pharmaceutically acceptable carrier.

2. The composition of claim 1 in a form suitable for injection.

3. The composition of claim 2 wherein R_1 and R_2 are independently chosen from the group consisting of C_2 - C_6 alkyl groups.

4. The composition of claim 3 wherein M^{+x} is chosen from the group consisting of group I and group II ions and $NR_3R_4R_5R_6^+$,


wherein R_3 , R_4 , R_5 and R_6 are independently chosen from the group consisting of H, C_1 - C_{12} alkyl, C_3 - C_7 cycloalkyl and benzyl.

5. The composition of claim 4 wherein R_1 and R_2 are ethyl.

6. The composition of claim 5 wherein M^{+x} is Na^+ , K^+ , Ca^{+2} or $N(C_2H_5)_2H_2^+$.

7. The composition of claim 2,3,4,5 or 6 wherein the pharmaceutically acceptable carrier is chosen from the group consisting of sterile water, phosphate buffered saline and aqueous glucose solutions.

8. A method of treating cardiovascular disorders in mammals by lowering the blood pressure which comprises administering to a mammal, in need thereof, a blood pressure lowering effective amount of a compound of the formula:



wherein R_1 and R_2 are independently chosen from the group consisting of a straight chain or branched chain C_1 - C_{12} alkyl group and a benzyl group, with the proviso that no branch occur on the alpha carbon atom, or R_1 and R_2 , together with the nitrogen atom they are bonded to, form a pyrrolidino, piperidino,

piperazino or morpholino group; and M^{+x} is a pharmaceutically acceptable cation, wherein x is the valence of the cation.

9. The method of claim 8 wherein the cardiovascular disorder is chronic hypertension, hypertensive crisis, acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency or intracranial haemorrhage.

10. The method of claim 9 wherein the cardiovascular disorder is hypertensive crisis, acute congestive heart failure or acute myocardial infarction.

11. The method of claim 8 wherein R_1 and R_2 are independently chosen from C_2 - C_6 alkyl groups.


12. The method of claim 11 wherein M^{+x} is chosen from the group consisting of group I and group II ions and $NR_3R_4R_5R_6^{+}$, wherein R_3 , R_4 , R_5 and R_6 are independently chosen from H, C_1 - C_{12} alkyl groups, C_3 - C_7 cycloalkyl or benzyl.

13. The method of claim 12 wherein R_1 and R_2 are ethyl.

14. The method of claim 13 wherein M^{+x} is Na^{+} , K^{+} , Ca^{+2} or $N(C_2H_5)_2H_2^{+}$.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/05018

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ²		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A61K 31/13; A61K 31/40; A61K 31/445; A61K 31/495; A61K 31/535		
U.S. CL.: 514/238.8; 514/255; 514/315; 514/426; 514/579; 514/611; 514/645		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	514/238.8; 514/255; 514/315; 514/426; 514/579; 514/611; 514/645	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶		
Chemical Abstracts-Subject 1909-1989		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US, A, 3,153,094 (REILLY) Published 13 October 1964, see entire reference.	1
Y	N, Drago, "Free Radicals in Inorganic Chemistry", No. 36, Advances in Chemistry Series, American Chemical Society, Washington, D.C., 1962 pages 143-149, see entire reference.	1
Y	N, Drago, "The Reaction of Nitrogen (II) Oxide with Various Primary and Secondary Amines", <u>J. Amer. Chem. Soc.</u> , (1961) pages 1819-1822.	1
* Special categories of cited documents: ¹⁵ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²		Date of Mailing of this International Search Report ²
04 DECEMBER 1990		28 DEC 1990
International Searching Authority ¹		Signature of Authorized Officer ²⁰
ISA/US		 ALLEN J. ROBINSON